Pasithea Therapeutics Q2 2025 Earnings Report

Pasithea Therapeutics EPS Results

• Actual EPS: -$0.66
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Pasithea Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Pasithea Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/14/2025
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Pasithea Therapeutics (NASDAQ:KTTA) (NASDAQ: KTTA) is a biotechnology company focused on developing novel therapies for serious diseases. The company’s current research and development activities center on PAS-004, an investigational allosteric MEK1/2 inhibitor designed to target the RAS/MAPK signaling pathway.

PAS-004 is being developed for potential use in conditions associated with abnormal pathway activation, including certain cancers and rare genetic disorders known as RASopathies. The program is intended to address limitations associated with earlier MEK inhibitors, although it remains an investigational product and has not been approved for commercial use.

Pasithea was originally established with a focus on innovative treatments for central nervous system disorders, including psychedelic-based approaches for mental health conditions. The company has since shifted its strategic emphasis toward its MEK inhibitor program and related therapeutic opportunities. Pasithea is based in the United States and operates as a development-stage biotechnology company.